Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 4/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.42 |
| ▸ | PDE4A | P27815 | 6/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6661044 | 0.94 | CCR5 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL6844062 | 0.91 | SMN1; SMN2 (0.50) | NPC1RAB9ASMN1; SMN2ABCG2PDE4D | |
| SCHEMBL6655460 | 0.90 | CCR5 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL6654216 | 0.90 | CCR5 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL6661791 | 0.89 | CCR5 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL6657461 | 0.89 | CCR5 (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL6658054 | 0.88 | CCR5 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1 | |
| SCHEMBL144452 | 0.88 | ABCG2 (0.54) | NPC1RAB9ASMN1; SMN2ALDH1A1ABCG2 | |
| SCHEMBL6683056 | 0.88 | LMNA (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1ABCG2 | |
| SCHEMBL6657658 | 0.88 | PDE4B (0.46) | NPC1RAB9ASMN1; SMN2ABCG2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2004-11-25 | — | — | US | disclosed |
| EP-1435958-A1 | USE OF PHOSPHORODIESTERASE IV INHIBITORS | MERCK PATENT GmbH (DE) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003032993-A1 | USE OF PHOSPHORODIESTERASE IV INHIBITORS | MERCK PATENT GMBH (DE) | 2003-04-24 | — | — | WO | disclosed |
| EP-0763534-B1 | Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors | MERCK PATENT GMBH (DE) | 2003-02-26 | — | — | EP | disclosed |
| US-5859008-A | Arylalkyl diazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-01-12 | — | — | US | disclosed |
| EP-0763534-A1 | Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors | MERCK PATENT GmbH (DE) | 1997-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | PDE4A, PDE3A, PDE3B | NPC1 3307/4885RAB9A 2053/4885SMN1; SMN2 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.